Table 1. Patient and event characteristics in the study population.
Data are given as counts, followed by percents in parentheses, except as otherwise noted.
| Arterial ischemic stroke (AIS) n=47 |
Venous thromboembolism (VTE) n=43 |
Overall (n = 90) | |
|---|---|---|---|
| Gender (female) | 16 (34%) | 22 (51%) | 38 (42%) |
| Race (self reported) | |||
| Caucasian (includes Hispanic) | 44 (94%) | 36 (84%) | 80 (89%) |
| Black | 0 | 6 (14%) | 6 (7%) |
| Native American/Native Alaskan | 2 (4%) | 0 | 2 (2%) |
| Other/more than one race | 1 (2%) | 1 (2%) | 2 (2%) |
| Asian | 0 | 0 | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 |
| Kidney disease | |||
| Acute | 1 (2%) | 2 (5%) | 3 (3%) |
| Chronic | 1 (2%) | 0 | 2 (2%) |
| Overt clinical prothrombotic risk factors1 | |||
| None | 28 (60%) | 6 (14%) | 34 (38%) |
| Confirmed infection (including cystic fibrosis) | 6 (13%) | 15 (35%) | 21 (23%) |
| Hospitalization/prolonged immobility | 1 (2%) | 12 (25%) | 13 (14%) |
| Catheter at site of thrombus | 1 (2%) | 11 (26%) | 12 (13%) |
| Vascular abnormality (Moyamoya, May Thurner, vasculitis) | 8 (17%) | 2 (5%) | 10 (11%) |
| Cardiac condition (congenital or acquired) | 7 (15%) | 2 (5%) | 9 (10%) |
| Trauma | 4 (9%) | 4 (9%) | 8 (9%) |
| Chronic inflammatory conditions (SLE, IBD) | 1 (2%) | 7 (16%) | 8 (9%) |
| Dehydration | 2 (4%) | 4 (9%) | 6 (7%) |
| Surgery | 2 (4%) | 3 (7%) | 5 (6%) |
| Oral contraceptive/estrogen use | 0 | 5 (12%) | 5 (6%) |
| Pregnancy | 0 | 4 (9%) | 4 (4%) |
| Malignancy | 1 (2%) | 2 (5%) | 3 (3%) |
| Acidosis | 0 | 2 (5%) | 2 (2%) |
| Smoking | 0 | 1 (2%) | 1 (1%) |
| Travel | 0 | 0 | 0 |
| Other Genetic Thrombophilias2 | |||
| Factor V Leiden | |||
| Heterozygous | 4 (9%) | 7 (16%) | 11 (12%) |
| Homozygous | 0 | 0 | 0 |
| Prothrombin G20210A | |||
| Heterozygous | 3 (6%) | 2 (5%) | 5 (6%) |
| Homozygous | 0 | 0 | 0 |
| Antithrombin deficiency | 0 | 0 | 0 |
| Protein C deficiency | 0 | 0 | 0 |
| Protein S deficiency | 0 | 3 (7%) | 3 (3%) |
1
Percentage totals may exceed 100% due to presence of more than one risk factor in many patients.
2
Two subjects had 2 thrombophilias each.
3
Extremity clots only, 20 subjects assessed.